Technical Analysis for CMRX - Chimerix, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| D | 0.94 | 6.33% | 0.06 |
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 6.33% | |
| Stochastic Buy Signal | Bullish | 6.33% | |
| NR7 | Range Contraction | 6.33% | |
| Narrow Range Bar | Range Contraction | 6.33% | |
| Inside Day | Range Contraction | 6.33% | |
| Oversold Stochastic | Weakness | 6.33% | |
| 50 DMA Resistance | Bearish | 6.33% | |
| MACD Bearish Centerline Cross | Bearish | 6.33% | |
| Gapped Up | Strength | 6.33% | |
| Oversold Stochastic | Weakness | 6.33% |
| Alert | Time |
|---|---|
| 60 Minute Opening Range Breakout | about 1 hour ago |
| Rose Above Previous Day's High | about 1 hour ago |
| Rose Above 50 DMA | about 1 hour ago |
| Rose Above 10 DMA | about 1 hour ago |
| Up 5% | about 1 hour ago |
Free Daily (Stock) Chart Reading
- Earnings date: 11/07/2024
Chimerix, Inc. Description
Chimerix, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of oral antiviral therapeutics for various medical needs. Its lead product includes CMX001, an orally administered drug that has completed Phase II clinical trials for the prevention of cytomegalovirus infection in hematopoietic stem cell transplant recipients; and is in Phase II clinical trials for treating double-stranded DNA viruses comprising herpesviruses, adenoviruses, BK viruses, papillomaviruses, and orthopoxviruses, as well as for the treatment of smallpox. The company also develops CMX157, an oral nucleotide compound that is in Phase I clinical trials to treat HIV infections. It has a collaboration and license agreement with Merck, Sharp & Dohme Corp. Chimerix, Inc. was founded in 2000 and is headquartered in Durham, North Carolina.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Viruses Virus Antiviral Drug Hematopoietic Stem Cell Herpes Papillomavirus Ebola Monkeypox Prodrugs Poxviruses Antivirals Orthopoxvirus
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 1.3 |
| 52 Week Low | 0.75 |
| Average Volume | 203,485 |
| 200-Day Moving Average | 0.95 |
| 50-Day Moving Average | 0.90 |
| 20-Day Moving Average | 0.94 |
| 10-Day Moving Average | 0.93 |
| Average True Range | 0.07 |
| RSI (14) | 43.82 |
| ADX | 19.14 |
| +DI | 14.89 |
| -DI | 15.23 |
| Chandelier Exit (Long, 3 ATRs) | 0.90 |
| Chandelier Exit (Short, 3 ATRs) | 1.05 |
| Upper Bollinger Bands | 1.05 |
| Lower Bollinger Band | 0.83 |
| Percent B (%b) | 0.23 |
| BandWidth | 23.57 |
| MACD Line | 0.00 |
| MACD Signal Line | 0.01 |
| MACD Histogram | -0.0143 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 0.93 | ||||
| Resistance 3 (R3) | 0.93 | 0.92 | 0.92 | ||
| Resistance 2 (R2) | 0.92 | 0.90 | 0.92 | 0.92 | |
| Resistance 1 (R1) | 0.90 | 0.90 | 0.91 | 0.90 | 0.92 |
| Pivot Point | 0.88 | 0.88 | 0.89 | 0.88 | 0.88 |
| Support 1 (S1) | 0.86 | 0.87 | 0.87 | 0.86 | 0.84 |
| Support 2 (S2) | 0.85 | 0.86 | 0.85 | 0.84 | |
| Support 3 (S3) | 0.83 | 0.85 | 0.84 | ||
| Support 4 (S4) | 0.83 |
